Bioactive glass nanoparticles induce intrinsic p53-dependent apoptosis and promote genomic instability via ROS overproduction and mitochondrial depolarization in triple-negative breast cancer cells

1. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363 (20), 1938–1948 (2010).

   Google Scholar 

2. Dawood, S. et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast. Cancer Res. Treat. 126(1) 185 – 92. https://doi.org/10.1007/s10549-010-1113-7. (2011).

3. Pal, T. et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer https://doi.org/10.1002/cncr.29645. (2015).

4. Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121 (7), 2750–2767 (2011).

   Google Scholar 

5. Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into molecular classifications, targeted therapies, and immunotherapy for triple-negative breast cancer. Cancer Discov. 9 (2), 176–198 (2019).

   Google Scholar 

6. Tutt, A. N. J. et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2105215. (2021).

7. Kim, E. S. Molecular targets and therapies associated with poor prognosis of triple–negative breast cancer (Review). Int. J. Oncol. https://doi.org/10.3892/ijo.2025.5758. (2025).

8. Wedam, R. et al. Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. Cancers (Basel). 15(7):1936. https://doi.org/10.3390/cancers15071936. (2023).

9. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (12), 751–760 (2007).

   Google Scholar 

10. Wang, Q. et al. Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study. Front Oncol. https://doi.org/10.3389/fonc.2019.00354. (2019).

11. Nguyen, S. M. et al. Chemotherapy-Induced Toxicities and Their Associations with Clinical and Non-Clinical Factors among Breast Cancer Patients in Vietnam. Curr. Oncol. 29(11) 8269–8284.https://doi.org/10.3390/curroncol29110653. (2022).

12. Hench, L. L. The story of Bioglass^®. J. Mater. Science: Mater. Med. 17 (11), 967–978 (2006).

    Google Scholar 

13. Wu, C. & Chang, J. Multifunctional mesoporous bioactive glasses for effective delivery of therapeutic ions and drug/growth factors. J. Controlled Release. 160 (3), 539–548 (2012).

    Google Scholar 

14. Hoppe, A., Güldal, N. S. & Boccaccini, A. R. A review of the biological response to ionic dissolution products from bioactive glasses. *Biomaterials* 32 (11), 2757–2774 (2011).

    Google Scholar 

15. Cannio, M., Bellucci, D., Roether, J. A., Boccaccini, D. N. & Cannillo, V. Bioactive Glass Applications: A Literature Review of Human Clinical Trials. Materials (Basel). 14(18) 5440. https://doi.org/10.3390/ma14185440. (2021).

16. Mouriño, V., Cattalini, J. P. & Boccaccini, A. R. Metallic ions as therapeutic agents in tissue engineering scaffolds: an overview of their biological applications and strategies for new developments. J. R. Soc. Interface. 9 (68), 401–419 (2012).

    Google Scholar 

17. Vichery, C. & Nedelec, J. M. Bioactive glass nanoparticles: from synthesis to materials design for biomedical applications. Materials 9 (4), 288. https://doi.org/10.3390/ma9040288 (2016).

    Google Scholar 

18. Borges, R. et al. Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment. Materials (Basel). 15(24):9082. https://doi.org/10.3390/ma15249082. (2022).

19. Drevet, R., Fauré, J. & Benhayoune, H. Electrophoretic deposition of bioactive glass coatings for bone implant applications: A review coatings 14, no. 9: 1084. https://doi.org/10.3390/coatings14091084 (2024).

20. Jones, J. R. Review of bioactive glass: from Hench to hybrids. Acta Biomater. 9(1) 4457-86. https://doi.org/10.1016/j.actbio.2012.08.023. (2013).

21. Szwed-Georgiou, A. et al. Bioactive Materials for Bone Regeneration: Biomolecules and Delivery Systems. ACS Biomater. Sci. Eng. 9(9) 5222–5254. https://doi.org/10.1021/acsbiomaterials.3c00609. (2023).

22. Fellenberg, J. et al. Bioactive glass selectively promotes cytotoxicity towards giant cell tumor of bone derived neoplastic stromal cells and induces MAPK signalling dependent autophagy. Bioact. Mater. (2022).

23. Deliormanlı, A. M., Rahman, B. & Atmaca, H. In vitro cytotoxicity of magnetic-fluorescent bioactive glasses on SaOS-2, MC3T3-E1, BJ fibroblast cells, their hemolytic activity, and sorafenib release behavior. Biomater. Adv. (2024).

24. Baino, F., Fiorilli, S. & Vitale-Brovarone, C. Bioactive glass-based materials with hierarchical porosity for medical applications: Review of recent advances. Acta Biomater. 42:18–32.https://doi.org/10.1016/j.actbio.2016.06.033. (2016).

25. Moeini, A., Chinijani, T. H. & Khachatourian, A. M. A critical review of bioactive glasses and glass–ceramics in cancer therapy. Int. J. Appl. Glass Sci. 14 (1), 69–87 (2023).

    Google Scholar 

26. Hussein, L., Moaness, M., Mabrouk, M., Farahat, M. G. & Beherei, H. H. Advancements in mesoporous bioactive glasses for effective bone cancer therapy: Recent developments and future perspectives. Biomater Biosyst. https://doi.org/10.1016/j.bbiosy.2025.100108. (2025).

27. Ren, Z. et al. Bioactive Glasses: Advancing Skin Tissue Repair through Multifunctional Mechanisms and Innovations. Biomater. Res. https://doi.org/10.34133/bmr.0134. (2025).

28. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65, 55–63 (1983).

    Google Scholar 

29. El-Zahabi, H. S. A. et al. New thiobarbituric acid scaffold-based small molecules: Synthesis, cytotoxicity, 2D-QSAR, pharmacophore modelling and in-silico ADME screening. Eur. J. Pharm. Sci. (2019).

30. Abdelsalam, E. A. et al. Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer. J. Enzyme Inhib. Med. Chem. 37 (1), 2265–2282. https://doi.org/10.1080/14756366.2022.2104841 (2022).

    Google Scholar 

31. Tice, R. R. et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35, 206–221 (2000).

    Google Scholar 

32. Langie, S. A., Azqueta, A. & Collins, A. R. The comet assay: past, present, and future. Front. Genet. 6, 266 (2015).

    Google Scholar 

33. Siddiqui, M. A. et al. Protective potential of trans-resveratrol against 4-hydroxynonenal induced damage in PC12 cells. Toxicol. Vitro. 24, 1592–1598 (2010).

    Google Scholar 

34. Zhang, Y. et al. Possible involvement of oxidative stress in potassium bromate-induced genotoxicity in human HepG2 cells. Chem. Biol. Interact. 189 (3), 186–191 (2011).

    Google Scholar 

35. Singh, N. P. A simple method for accurate estimation of apoptotic cells. Exp. Cell Res. 256(1) 328 – 37. https://doi.org/10.1006/excr.2000.4810. (2000).

36. Guan, X. & Guan, Y. Artemisinin induces selective and potent anticancer effects in drug resistant breast cancer cells by inducing cellular apoptosis and autophagy and G2/M cell cycle arrest. J. BUON. 25 (3), 1330–1336 (2020).

    Google Scholar 

37. Suzuki, K. et al. Drug- induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro. Jpn J. Clin. Oncol. 29 (7), 323–331 (1999).

    Google Scholar 

38. Lai, C. Y. et al. Aciculatin induces p53-dependent apoptosis via mdm2 depletion in human cancer cells in vitro and in vivo. PLoS ONE. 7 (8), e42192 (2013).

    Google Scholar 

39. Grzybowska-Szatkowska, L. & Ślaska, B. Mitochondrial NADH dehydrogenase polymorphisms are associated with breast cancer in Poland. J. Appl. Genet. 55, 173–181 (2014).

    Google Scholar 

40. Obidiro, O., Battogtokh, G. & Akala, E. O. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics 15(7) 1796. https://doi.org/10.3390/pharmaceutics15071796. (2023).

41. Chapdelaine, A. G. & Sun, G. Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer. Biomolecules. https://doi.org/10.3390/biom13081207. (2023).

42. Morelli, M. B. et al. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Front. Cardiovasc. Med. (2022).

43. Wang, J. & Wu, S. G. Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives. Breast Cancer (Dove Med Press). (2023).

44. Newton, E. E., Mueller, L. E., Treadwell, S. M., Morris, C. A. & Machado, H. L. Molecular Targets of Triple-Negative Breast Cancer: Where Do We Stand? Cancers (Basel). 14(3):482. https://doi.org/10.3390/cancers14030482. (2022).

45. Chehelgerdi, M. et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol. Cancer. 22 (1), 169. https://doi.org/10.1186/s12943-023-01865-0 (2023).

    Google Scholar 

46. Sabir, S., Thani, A. S. B. & Abbas, Q. Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance. Front Bioeng. Biotechnol.https://doi.org/10.3389/fbioe.2025.1548588. (2025).

47. Pajares-Chamorro, N. & Chatzistavrou, X. Bioactive Glass Nanoparticles for Tissue Regeneration. ACS Omega. https://doi.org/10.1021/acsomega.0c00180. (2020).

48. Ali, H. M. et al. Reactive oxygen species induced oxidative damage to DNA, lipids, and proteins of antibiotic-resistant bacteria by plant-based silver nanoparticles. 3 Biotech. https://doi.org/10.1007/s13205-023-03835-1. (2023).

49. Mohamed, H. R. H. et al. Yttrium oxide nanoparticles ameliorates calcium hydroxide and calcium titanate nanoparticles induced genomic DNA and mitochondrial damage, ROS generation and inflammation. Sci. Rep. (2024)https://doi.org/10.1038/s41598-024-62877-4 (2024).

50. Mohamed, H. R. H. et al. Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells. Sci Rep. https://doi.org/10.1038/s41598-025-05088-9. (2025).

51. Baracca, A., Sgarbi, G., Solaini, G. & Lenaz, G. Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F(0) during ATP synthesis. Biochim. Biophys. Acta https://doi.org/10.1016/s0005-2728(03)00110-5. (2023).

52. Zong, Y. et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct. Target. Ther. https://doi.org/10.1038/s41392-024-01839-8. (2024).

53. Adinew, G. M., Messeha, S. S., Taka, E., Badisa, R. B. & Soliman, K. F. A. Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells. Nutrients https://doi.org/10.3390/nu14224787. (2022).

54. Bel’skaya, L. V. & Dyachenko, E. I. Oxidative Stress in Breast Cancer: A Biochemical Map of Reactive Oxygen Species Production. Curr. Issues Mol. Biol. https://doi.org/10.3390/cimb46050282. (2024).

55. Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35 (4), 495–516 (2007).

    Google Scholar 

56. Rose, R. et al. Chromatin compaction precedes apoptosis in developing neurons. Commun. Biol. 5 (1), 797. https://doi.org/10.1038/s42003-022-03704-2 (2022).

    Google Scholar 

57. Fulda, S., Galluzzi, L. & Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discover.. 9 (6), 447–464. https://doi.org/10.1038/nrd3137 (2010).

    Google Scholar 

58. Jan, R. & Chaudhry, G. E. Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics. Adv. Pharm. Bull. https://doi.org/10.15171/apb.2019.024. (2019).

59. Mustafa, M. et al. Apoptosis: A comprehensive overview of signaling Pathways, morphological Changes, and physiological significance and therapeutic implications. Cells 13 (22), 1838. https://doi.org/10.3390/cells13221838 (2024).

    Google Scholar 

60. Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat. Rev. Drug Discovery. 8 (7), 579–591. https://doi.org/10.1038/nrd2803 (2009).

    Google Scholar 

61. Tamanna, S., Perumal, E. & Rajanathadurai, J. Enhanced Apoptotic Effects in MDA-MB-231 Triple-Negative Breast Cancer Cells Through a Synergistic Action of Luteolin and Paclitaxel. Cureus https://doi.org/10.7759/cureus.65159. (2024).

62. Guo, C., Sun, L., Chen, X. & Zhang, D. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural. Regen. Res. https://doi.org/10.3969/j.issn.1673-5374.2013.21.009. (2013).

63. Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A. & D’Orazi, G. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). https://doi.org/10.18632/aging.100934. (2016).

64. Liu, S. et al. Oxidative Stress: Signaling Pathways, Biological Functions, and Disease. https://doi.org/10.1002/mco2.70268. (2025).

65. Mohamed, H. R. H. et al. Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells. Sci Rep. https://doi.org/10.1038/s41598-025-05088-9. (2025).

66. Mohamed, H. R., Hemdan, S. H. A. & El-Sherif, A. A. Y2O3NPs induce selective cytotoxicity, genomic instability, oxidative stress and ROS mediated mitochondrial apoptosis in human epidermoid skin A-431 Cancer cells. Sci Rep. https://doi.org/10.1038/s41598-024-82376-w. (2025).

67. Mohamed, H. R. H. et al. Induction of potent Preferential cell death, severe DNA damage and p53-independent ROS-mediated mitochondrial apoptosis by CaTiO3NPs in HNO-97 tongue cancer cells. Naunyn Schmiedebergs Arch. Pharmacol.. 4 https://doi.org/10.1007/s00210-025-04323-4 (2025).

68. Pitolli, C. et al. p53-Mediated tumor suppression: DNA-Damage response and alternative mechanisms. Cancers (Basel). 11 (12), 1983. https://doi.org/10.3390/cancers11121983 (2019).

    Google Scholar 

69. Hernández Borrero, L. J. & El-Deiry, W. S. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim. Biophys. Acta Rev. Cancer. 1876 (1), 188556. https://doi.org/10.1016/j.bbcan.2021.188556 (2021).

    Google Scholar 

70. Qayoom, H. et al. Targeting mutant p53: a key player in breast cancer pathogenesis and beyond. Cell Commun. Signal. https://doi.org/10.1186/s12964-024-01863-9. (2024).

71. Wang, D. B., Kinoshita, C., Kinoshita, Y. & Morrison, R. S. p53 and mitochondrial function in neurons. Biochim. Biophys. Acta. https://doi.org/10.1016/j.bbadis.2013.12.015. (2014).

72. Chung, J. Y. & Knutson, B. A. Bypassing the guardian: regulated cell death pathways in p53-mutant cancers. Cell. Mol. Biol. Lett. https://doi.org/10.1186/s11658-025-00751-5. (2025).

73. Vogler, M. et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct Target Ther. https://doi.org/10.1038/s41392-025-02176-0. (2025).

74. Qian, S. et al. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. https://doi.org/10.3389/fonc.2022.985363. (2022).

75. Safwat, G., Soliman, E. S. M. & Mohamed, H. R. H. Induction of ROS mediated genomic instability, apoptosis and G0/G1 cell cycle arrest by erbium oxide nanoparticles in human hepatic Hep-G2 cancer cells. Sci. Rep. https://doi.org/10.1038/s41598-022-20830-3. (2022).

76. Mohamed, H. R. H. et al. Calcium titanate nanoparticles-induced cytotoxicity, genotoxicity and oxidative stress in human non-small lung cancer cells. Sci. Rep. https://doi.org/10.1038/s41598-025-89035-8 (2025).

77. Mohamed, H. R. H., Ibrahim, M. M. H. & Diab, A. Induction of oxidative DNA damage, cell cycle arrest and p53 mediated apoptosis by calcium titanate nanoparticles in MCF-7 breast cancer cells. Cancer Cell. Int. 22 (1), 355. https://doi.org/10.1186/s12935-022-02780-y (2022).

    Google Scholar 

78. Liu, J. et al. Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer. Naunyn Schmiedebergs Arch. Pharmacol. 396 (2), 365–374. https://doi.org/10.1007/s00210-022-02316-1 (2023).

    Google Scholar 

79. Xu, X., Pang, Y. & Fan, X. Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances. Signal Transduct. Target. Ther. https://doi.org/10.1038/s41392-025-02253-4. (2025).

Download references